Internal Reference Number: FOI_8769
Date Request Received: 11/07/2025 00:00:00
Date Request Replied To: 28/07/2025 00:00:00
This response was sent via: By Email
Request Summary: Ovarian Cancer questions
Request Category: Private Individuals
| Question Number 1: I鈥檓 hoping that you will be able to help me with Freedom of Information request that I have, can you please tell me How many patients have been treated for advanced (FIGO Stages III and IV) ovarian (epithelial ovarian, fallopian tube or primary peritoneal) cancer over the last 3 months? If none, do you refer advanced ovarian cancer patients to another trust, and if so which one? | |
| Answer To Question 1: 29 patients | |
| Question Number 2: How many ovarian cancer patients (any stage) have been treated in the last 3 months with: Paclitaxel in combination with a platinum-based compound Platinum-based therapy alone (cisplatin or carboplatin) Bevacizumab in combination with paclitaxel and carboplatin Olaparib Olaparib + Bevacizumab Niraparib Rucaparib | |
| Answer To Question 2: Paclitaxel with platinum <5 patients, platinum alone 5 patients, Bevacizumab in combination 9 patients, Olaparib 5 patients, Olap + bev ,<5 patients, niraparib <5 patients, rucaparib <5 patients. | |
| Question Number 3: Does your trust participate in any clinical trials for the treatment of ovarian cancer? If so, please provide the name of each trial along with the number of patients taking part | |
| Answer To Question 3: There's currently no ovarian studies in the pipeline, however we previously participated in 3 studies 1. HORIZONS: Understanding the impact of cancer diagnosis and treatment - We recruited 58 patients 2. Developing new tests for ovarian cancer - we recruited 1 patient 3. mOEC (A GCIG Intergroup multicentre trial of open label carboplatin and paclitaxel +/- bevacizumab compared with oxaliplatin and capecitabine +/- bevacizumab as first line chemotherapy in patients with mucinous Epithelial Ovarian Cancer) - no patient was recruited to this study. Pharmacy response: None | |
| Question Number 4: If data for HRD (homologous recombination deficiency) testing is available, please provide how many HRD positive patients were treated in the last 3 months with: Olaparib Olaparib + Bevacizumab Niraparib Other treatments | |
| Answer To Question 4: Olaparib 5 patients, Ola +bev <5 patients, niraparib zero other zero | |
| To return to the list of all the FOI requests please click here |
Our staff at 91影视 District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
